SG11201811107WA - Heteroaromatic modulators of the retinoid-related orphan receptor gamma - Google Patents
Heteroaromatic modulators of the retinoid-related orphan receptor gammaInfo
- Publication number
- SG11201811107WA SG11201811107WA SG11201811107WA SG11201811107WA SG11201811107WA SG 11201811107W A SG11201811107W A SG 11201811107WA SG 11201811107W A SG11201811107W A SG 11201811107WA SG 11201811107W A SG11201811107W A SG 11201811107WA SG 11201811107W A SG11201811107W A SG 11201811107WA
- Authority
- SG
- Singapore
- Prior art keywords
- alkyl
- cycloalkyl
- ballerup
- membered
- international
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title abstract 3
- 102100023421 Nuclear receptor ROR-gamma Human genes 0.000 title abstract 2
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020268 | 2016-07-13 | ||
| PCT/EP2017/067390 WO2018011201A1 (fr) | 2016-07-13 | 2017-07-11 | Modulateurs hétéroaromatiques du récepteur gamma orphelin associé aux rétinoïdes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811107WA true SG11201811107WA (en) | 2019-01-30 |
Family
ID=56511303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811107WA SG11201811107WA (en) | 2016-07-13 | 2017-07-11 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10662181B2 (fr) |
| EP (1) | EP3484880B1 (fr) |
| JP (1) | JP7016344B2 (fr) |
| KR (1) | KR102490140B1 (fr) |
| CN (1) | CN109476653B (fr) |
| AU (1) | AU2017294969B2 (fr) |
| BR (1) | BR112019000486A2 (fr) |
| CA (1) | CA3030370A1 (fr) |
| DK (1) | DK3484880T3 (fr) |
| ES (1) | ES2834009T3 (fr) |
| IL (1) | IL264141B (fr) |
| MX (1) | MX383770B (fr) |
| MY (1) | MY196990A (fr) |
| PL (1) | PL3484880T3 (fr) |
| PT (1) | PT3484880T (fr) |
| RU (1) | RU2771280C2 (fr) |
| SA (1) | SA519400868B1 (fr) |
| SG (1) | SG11201811107WA (fr) |
| UA (1) | UA123330C2 (fr) |
| WO (1) | WO2018011201A1 (fr) |
| ZA (1) | ZA201808436B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019000486A2 (pt) * | 2016-07-13 | 2019-04-24 | Leo Pharma A/S | composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase |
| CN111825654A (zh) * | 2019-04-19 | 2020-10-27 | 北京酷瓴生物技术有限公司 | 苯甲烯哌啶衍生物及其制备方法、中间体和用途 |
| CN112898292A (zh) * | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS244821B2 (en) | 1983-06-16 | 1986-08-14 | Boehringer Ingelheim Ltd | Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas |
| WO2004073612A2 (fr) | 2003-02-13 | 2004-09-02 | Merck & Co. Inc. | Modulateurs de recepteur d'oestrogenes |
| FR2879381B1 (fr) | 2004-12-15 | 2008-12-26 | Thales Sa | Systeme de distribution quantique de cle de cryptage a variables continues |
| UA95071C2 (ru) * | 2005-04-04 | 2011-07-11 | Аб Сьянс | Замещенные производные оксазола и их применение как ингибиторов тирозинкиназы |
| EP2511275A1 (fr) * | 2011-04-12 | 2012-10-17 | Bioprojet | Nouveaux acides pipéridiniles monocarboxyliques comme agonistes du récepteur S1P1 |
| PE20151144A1 (es) | 2012-12-06 | 2015-08-02 | Glaxo Group Ltd | Moduladores de la orphan receptor gamma retinoides relacionados (ror - gamma) para uso en el tratamiento de las enfermedades autoinmunes e inflamatorias |
| CA2929194A1 (fr) | 2013-11-05 | 2015-05-14 | F. Hoffmann-La Roche Ag | Derives de 5,6,7,8-tetrahydro-5,8-methanocinnoline a titre de modulateurs rorc pour le traitement des maladies auto-immunes |
| KR20170012388A (ko) | 2014-05-28 | 2017-02-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 신규 화합물 |
| JP6759110B2 (ja) * | 2014-05-28 | 2020-09-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 新規な化合物 |
| ES2716966T3 (es) | 2014-05-28 | 2019-06-18 | Glaxosmithkline Ip Dev Ltd | Derivados de piperazina como moduladores de ROR-gamma |
| BR112019000486A2 (pt) * | 2016-07-13 | 2019-04-24 | Leo Pharma A/S | composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar psoríase |
-
2017
- 2017-07-11 BR BR112019000486-6A patent/BR112019000486A2/pt active Search and Examination
- 2017-07-11 ES ES17737284T patent/ES2834009T3/es active Active
- 2017-07-11 MX MX2019000361A patent/MX383770B/es unknown
- 2017-07-11 EP EP17737284.4A patent/EP3484880B1/fr active Active
- 2017-07-11 PT PT177372844T patent/PT3484880T/pt unknown
- 2017-07-11 WO PCT/EP2017/067390 patent/WO2018011201A1/fr not_active Ceased
- 2017-07-11 AU AU2017294969A patent/AU2017294969B2/en not_active Ceased
- 2017-07-11 MY MYPI2018002824A patent/MY196990A/en unknown
- 2017-07-11 CN CN201780043425.2A patent/CN109476653B/zh not_active Expired - Fee Related
- 2017-07-11 SG SG11201811107WA patent/SG11201811107WA/en unknown
- 2017-07-11 KR KR1020197003804A patent/KR102490140B1/ko active Active
- 2017-07-11 CA CA3030370A patent/CA3030370A1/fr active Pending
- 2017-07-11 DK DK17737284.4T patent/DK3484880T3/da active
- 2017-07-11 RU RU2019103883A patent/RU2771280C2/ru active
- 2017-07-11 JP JP2019501569A patent/JP7016344B2/ja not_active Expired - Fee Related
- 2017-07-11 UA UAA201901406A patent/UA123330C2/uk unknown
- 2017-07-11 US US16/317,655 patent/US10662181B2/en active Active
- 2017-07-11 PL PL17737284T patent/PL3484880T3/pl unknown
-
2018
- 2018-12-13 ZA ZA2018/08436A patent/ZA201808436B/en unknown
-
2019
- 2019-01-08 IL IL264141A patent/IL264141B/en unknown
- 2019-01-13 SA SA519400868A patent/SA519400868B1/ar unknown
-
2020
- 2020-05-15 US US16/874,961 patent/US10934282B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX383770B (es) | 2025-03-14 |
| NZ749301A (en) | 2021-03-26 |
| DK3484880T3 (da) | 2020-11-09 |
| US10934282B2 (en) | 2021-03-02 |
| RU2019103883A (ru) | 2020-08-13 |
| AU2017294969A1 (en) | 2019-01-17 |
| BR112019000486A2 (pt) | 2019-04-24 |
| EP3484880B1 (fr) | 2020-09-02 |
| IL264141A (en) | 2019-02-28 |
| CN109476653A (zh) | 2019-03-15 |
| RU2019103883A3 (fr) | 2020-09-23 |
| US20190284177A1 (en) | 2019-09-19 |
| KR20190026872A (ko) | 2019-03-13 |
| PT3484880T (pt) | 2020-12-07 |
| US10662181B2 (en) | 2020-05-26 |
| SA519400868B1 (ar) | 2022-06-13 |
| WO2018011201A1 (fr) | 2018-01-18 |
| CN109476653B (zh) | 2022-04-22 |
| JP7016344B2 (ja) | 2022-02-04 |
| PL3484880T3 (pl) | 2021-04-06 |
| JP2019521137A (ja) | 2019-07-25 |
| MX2019000361A (es) | 2019-05-23 |
| EP3484880A1 (fr) | 2019-05-22 |
| UA123330C2 (uk) | 2021-03-17 |
| US20200291010A1 (en) | 2020-09-17 |
| ES2834009T3 (es) | 2021-06-16 |
| MY196990A (en) | 2023-05-17 |
| AU2017294969B2 (en) | 2021-03-25 |
| RU2771280C2 (ru) | 2022-04-29 |
| IL264141B (en) | 2021-09-30 |
| ZA201808436B (en) | 2020-05-27 |
| CA3030370A1 (fr) | 2018-01-18 |
| KR102490140B1 (ko) | 2023-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201808678QA (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201908097YA (en) | Pyrimidine derivatives as pge2 receptor modulators | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201903908PA (en) | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201403402VA (en) | Compounds | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201909793YA (en) | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201908729UA (en) | Phenyl derivatives as pge2 receptor modulators | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909615YA (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide |